Welcome
Support Centre
12 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Neural correlates of cognitive motor interference (CMI) while walking
ISRCTN ISRCTN59902842
ClinicalTrials.gov identifier
Public title Neural correlates of cognitive motor interference (CMI) while walking
Scientific title Cortical activation of cognitive motor interference while walking: a near-infrared spectroscopic study
Acronym CMI
Serial number at source TSA 2007/09
Study hypothesis 1. There may be a relationship between the degree of regional brain activation and/or the temporal activation pattern and performance in cognitive and motor tasks under dual task conditions
2. This relationship may be different following a stroke than in healthy controls
Lay summary
Ethics approval Oxfordshire Research Ethics Committee C, approved on 24th July 2008 (ref: 08/H0606/55)
Study design Observational cross-sectional study
Countries of recruitment United Kingdom
Disease/condition/study domain Stroke
Participants - inclusion criteria Patients will be selected from those treated in the Oxford Radcliffe Hospitals who are:
1. More than 6 months following a first stroke
2. Both males and females, aged 45 to 80 years
3. With an ischaemic infarct upon computed tomography (CT) or magnetic resonance imaging (MRI) scan
3. Able to perform a simple reciprocal bilateral foot tapping task, walk safely on a treadmill with or without mobility aids
4. Be able to give informed consent

Sex and age-matched controls will be chosen who do not have a known neurological disease, a history of hypertension, cardiac disease or diabetes.
Participants - exclusion criteria 1. Dementia
2. Aphasia significantly limiting communication
3. History of previous symptomatic strokes or neurological disease
4. Known psychiatric disease or claustrophobia, or other conditions precluding safe MRI (e.g., pacemaker or other metal implant)
Anticipated start date 01/07/2008
Anticipated end date 01/07/2010
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 36
Interventions Baseline assessments include:
1. The Mini Mental State Examination: the MMSE is a brief screening tool to provide quantitative assessment of cognitive function. It consists of 11 simple questions or tasks. Typically, they are grouped into seven domains; orientation to time, orientation to place, registration of three words, attention and calculation.
2. Edinburgh Handedness Inventory: this is a brief questionnaire of 10 short items, which determines subject's hand dominance.
3. Barthel Index: a simple index of independence in activities of daily living (ADL). It consists of 10 common ADL activities, which they are assessed for independence/dependence.
4. Modified Physical Activity Scale for the elderly: a self reported physical activity questionnaire that covers one week.
5. Berg Balance Scale (BBS): the BBS provides a quantitative assessment of balance. It consists of 14 items requiring subjects to maintain or complete movement tasks of varying levels of difficulty. All items are common to everyday life.

The results of the assessments above will be reported together with the primary/secondary outcomes, as they might correlate with differences in CMI.

Brain activation in both stroke and control subjects will be examined by near-infrared spectroscopy (NIRS) alongside behavioural performance of walking and cognitive tasks (calculation). The participants will be asked to perform the concurrent tasks when seated and walking. Gait parameters will be measured using a well-validated gait analysis system (Xsens, The Netherlands).
Primary outcome measure(s) Task related changes in oxygenated and deoxygenated haemoglobins in the frontal lobe as measured by NIRS.
Secondary outcome measure(s) 1. Rate of backward calculation (number per minute)
2. Number of errors in backward calculation (errors per trial)
3. Spatiotemporal gait measures (speed, cadence, step time, stride time, step length, stride length, step width)
Sources of funding The Stroke Association (UK) (ref: TSA 2007/09)
Trial website
Publications
Contact name Dr  Helen  Dawes
  Address School of Life Sciences
Oxford Brookes University
  City/town Oxford
  Zip/Postcode OX3 0BP
  Country United Kingdom
Sponsor Oxford Brookes University (UK)
  Address c/o Prof Linda King
School of Life Sciences
  City/town Oxford
  Zip/Postcode OX3 0BP
  Country United Kingdom
  Sponsor website: http://www.brookes.ac.uk
Date applied 17/11/2008
Last edited 27/11/2008
Date ISRCTN assigned 27/11/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central